- Home
- NDLS vs BNR Comparison
NDLS vs BNR Comparison
Compare NDLS & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- BNR
- Stock Information
- Founded
- NDLS 1995
- BNR 2014
- Country
- NDLS United States
- BNR China
- Employees
- NDLS N/A
- BNR N/A
- Industry
- NDLS Restaurants
- BNR Medical Specialities
- Sector
- NDLS Consumer Discretionary
- BNR Health Care
- Exchange
- NDLS Nasdaq
- BNR Nasdaq
- Market Cap
- NDLS 32.9M
- BNR 38.3M
- IPO Year
- NDLS 2013
- BNR 2020
- Fundamental
- Price
- NDLS $0.87
- BNR $4.68
- Analyst Decision
- NDLS Strong Buy
- BNR
- Analyst Count
- NDLS 2
- BNR 0
- Target Price
- NDLS $3.00
- BNR N/A
- AVG Volume (30 Days)
- NDLS 235.4K
- BNR 17.4K
- Earning Date
- NDLS 08-06-2025
- BNR 08-21-2025
- Dividend Yield
- NDLS N/A
- BNR N/A
- EPS Growth
- NDLS N/A
- BNR N/A
- EPS
- NDLS N/A
- BNR N/A
- Revenue
- NDLS $495,670,000.00
- BNR $72,112,038.00
- Revenue This Year
- NDLS $5.37
- BNR $136.32
- Revenue Next Year
- NDLS $0.68
- BNR N/A
- P/E Ratio
- NDLS N/A
- BNR N/A
- Revenue Growth
- NDLS N/A
- BNR 0.53
- 52 Week Low
- NDLS $0.55
- BNR $2.18
- 52 Week High
- NDLS $1.83
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- NDLS 59.19
- BNR 69.57
- Support Level
- NDLS $0.80
- BNR $4.47
- Resistance Level
- NDLS $0.92
- BNR $4.96
- Average True Range (ATR)
- NDLS 0.07
- BNR 0.25
- MACD
- NDLS 0.01
- BNR 0.11
- Stochastic Oscillator
- NDLS 88.89
- BNR 84.31
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.